Filing Details

Accession Number:
0001140361-17-041378
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-07 16:07:08
Reporting Period:
2017-11-03
Accepted Time:
2017-11-07 16:07:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367644 Emergent Biosolutions Inc. EBS Pharmaceutical Preparations (2834) 141902018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380187 Daniel Abdun-Nabi 400 Professional Dr, Suite 400
Gaithersburg MD 20879
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-03 11,508 $22.03 215,642 No 4 M Direct
Common Stock Disposition 2017-11-03 11,508 $42.50 204,134 No 4 S Direct
Common Stock Acquisiton 2017-11-03 20,000 $14.44 224,134 No 4 M Direct
Common Stock Disposition 2017-11-03 20,000 $42.92 204,134 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-11-03 11,508 $0.00 11,508 $22.03
Common Stock Stock Option (Right to Buy) Disposition 2017-11-03 20,000 $0.00 20,000 $14.44
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-03-14 No 4 M Direct
41,906 2019-03-12 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,000 Indirect By Son
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive.
  4. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  5. Consists of an option granted under the company's stock incentive plan as amended and restated.
  6. The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.